| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Over the past 90 days, insiders at Novabridge Biosciences (NBP) have been net sellers, shedding 119,469 shares worth roughly $88K on balance.
NBP sits in the Biotechnology industry within the Healthcare sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| VP | 304.2K | $240.3K | - | |
| Other | 266.5K | $197.2K | - | |
| Other | 230.0K | $577.3K | - | |
| Other | 173.4K | $123.1K | - | |
| Dir | 17.2K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Dennis Phillip Andrew | Chief Medical Officer | Sale+OE | 8,209 | $0.71 | $5,828.39 | -4.5% | - | - | |
| Sep 9, 2026 | Cao Sean Wuxiong | Chief Bus. Development Officer | Sell | 107,978 | $0.74 | $79,903.72 | -28.8% | - | - | |
| Aug 31, 2026 | Xu Cong Claire | EVP, Clinical Development | Sale+OE | 3,282 | $0.79 | $2,592.78 | -1.1% | - | - | |
| Jul 6, 2026 | Xu Cong Claire | SVP, Clinical Development | Sale+OE | 4,485 | $0.89 | $3,991.65 | -1.5% | -32.3% | - | |
| Jun 18, 2026 | Dennis Phillip Andrew | Chief Medical Officer | Sale+OE | 8,494 | $0.66 | $5,606.04 | -5.1% | +4.7% | - | |
| Jun 1, 2026 | Xu Cong Claire | SVP, Clinical Development | Sale+OE | 3,494 | $3.94 | $13,766.36 | -1.2% | +6.4% | - | |
| May 14, 2026 | Cao Sean Wuxiong | See Remarks | Sell | 21,399 | $1.99 | $42,584.01 | -37.9% | -2.6% | - | |
| Apr 24, 2026 | Hagler Mark Arnold | See Remarks | Buy | 230,000 | $2.51 | $577,300.00 | New | -27.8% | - |